Skip to main content
Premium Trial:

Request an Annual Quote

Five RNAi-Related Patent Applications Published by the USPTO: Sep 30, 2005

Premium

Title: Nucleic Acid-Mediated Inhibition of Enterococcus Infection and Cytolysin Toxin Activity

Number: 20050209182

Filed: Dec. 14, 2004

Lead Inventor: David Morrissey, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to nucleic acid aptamers that bind to bacterial proteases such as CylA and methods for their use alone or in combination with other therapies, such as antibiotics. Also disclosed are nucleic acids such as siRNA, antisense, and enzymatic nucleic acid molecules that can modulate the expression of CylA genes. The compounds and methods of the invention are expected to inhibit enterococcus infection and cytolysin activity," the abstract notes.


Title: RNA Interference-Mediated Inhibition of Hepatitis C Virus Expression Using Short Interfering Nucleic Acid

Number: 20050209180

Filed: Sept. 15, 2004

Lead Inventor: Vasant Jadhav, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating HCV gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HCV gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of HCV genes."


Title: RNA Interference-Mediated Treatment of Alzheimer's Disease Using Short Interfering Nucleic Acid

Number: 20050209179

Filed: June 25, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating beta-secretase, amyloid precurson protein, PIN-1, presenillin 1, and/or presenillin 2 gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of BACE, APP, PIN-1, PS-1, and/or PS-2 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of BACE, APP, PIN-1, PS-1, and/or PS-2 genes."


Title: RNA Interference-Mediated Inhibition of 11Beta Hydroxysteriod Dehydrogenase-1 Gene Expression

Number: 20050208658

Filed: Nov. 19, 2004

Inventor: Thomas Castonguay, University of Maryland

According to the patent application's abstract, the invention relates "to compositions comprising double stranded RNA capable of inhibiting the expression of the gene encoding 11beta HSD-1, and methods of using the compositions in therapeutic, prophylactic, and research methods."


Title: Methods and Apparatus for Determination of RNAi Cell Transfection Effects by Multiple Gene Expression Analysis on Microarrays

Number: 20050208518

Filed: Nov. 12, 2004

Lead Inventor: Francoise de Longueville, Eppendorf Array Technologies

"The invention provides a tool and a method for the easy interpretation of the changes occurring in a cell, being a three dimensional complex and control system when transfected by RNAi," the patent application states. "The method is based on the analysis of a limited number of data obtained by quantifying the intensity of the signals present on spots distributed in a two dimensional surface. The invention allows to observe the effects of the presence of a particular RNAI on the cells main vital cellular functions together with the possible side or deleterious effects resulting from the transfection process or to the presence of the RNAi in a cell," the abstract adds. "The invention also provides a method for the determination of change in the three dimensional status of a cell, wherein an array containing nucleic acids or proteins belonging to or being representative for at least 5 vital cellular functions together with 3 deleterious functions."

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.